European Medicines Agency Research Grant
03/05/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC9236Ja&default-theme=true
RNS Number : 9236J Instem plc 03 May 2022
Instem plc
("Instem", the "Group" or the "Company")
European Medicines Agency Research Grant
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces that it has secured funding as part of a €2.5m
European Medicines Agency ("EMA") grant - with the Company receiving c.12.5%
of funds invested by the EMA.
As part of an industry and academic consortium of nine beneficiaries, funded
by EMA and led by Fraunhofer Institute for Toxicology and Experimental
Medicine (ITEM), Instem is collaborating on a two-year research project to
further investigate the mutagenicity of different classes of N-nitrosamines
("NAs"). Humans may be exposed to this class of organic chemical compounds
by consuming certain foods, or through tobacco use. Some active pharmaceutical
ingredients also carry NAs as impurities from production and/or storage or may
cause their formation in the gastrointestinal tract. Consequently, NA
related risk has become a focus for pharmaceutical and other regulatory
authorities around the world. The project will aim to distinguish highly
potent from less potent carcinogens.
Experts from Instem's In Silico Solutions group will be participating in the
project, and its Leadscope Model Applier computational toxicology software
suite and toxicity and carcinogenicity databases will be used to help the
consortium develop novel in silico test systems that will improve risk
assessment and derive reference doses such as acceptable intake values.
Renowned for its advanced informatics and prediction technology, together with
comprehensive database solutions, Instem's in silico solutions enable
organizations around the world to effectively unlock valuable knowledge
contained in both public and proprietary sources of research data. Its clients
can access over 500,000 toxicology studies for more than 200,000 chemicals,
enabling fast, accurate, defendable and regulatory-accepted predictions.
Dr. Glenn Myatt, VP Informatics, Instem commented: "The Leadscope Model
Applier software solution includes a comprehensive package of models to meet
the growing market demand for in silico solutions. The award of this grant
highlights the strength of our product suite, which supports the continued
global demand for reliable alternatives to traditional testing methods - with
industry and regulators alike increasingly recognizing the huge benefits of
computational toxicology approaches.
"We are delighted to have been invited to contribute to this important
research program and to have the opportunity to work with leading researchers
in developing new testing methodologies to help reduce drug safety risks."
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAILMJTMTJTBMT